The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neutrophil-to-lymphocyte ratio as a prognostic marker in patients with metastatic gallbladder cancer.
 
Mohamed Mady
No Relationships to Disclose
 
Kritika Prasai
No Relationships to Disclose
 
Siddhartha Yadav
No Relationships to Disclose
 
Mohamed Abdelrahim Muddathir Hassan
No Relationships to Disclose
 
Lewis R. Roberts
Consulting or Advisory Role - Bayer (Inst); Exact Sciences (Inst); GRAIL (Inst); RedHill Biopharma (Inst); TAVEC (Inst)
Speakers' Bureau - Bayer
Research Funding - ARIAD (Inst); BTG (Inst); Exact Sciences (Inst); Gilead Sciences (Inst); Wako Diagnostics (Inst)
Patents, Royalties, Other Intellectual Property - US Patent No. 9,469,877: Materials and Methods for Diagnosis, Prognosis, Monitoring of Recurrence and Assessment of Therapeutic/Prophylactic Treatment of Pancreaticobiliary Cancer (Inst)
 
Mitesh J. Borad
Stock and Other Ownership Interests - AVEO; Gilead Sciences; GlaxoSmithKline
Consulting or Advisory Role - Agios (Inst); ArQule (Inst); Celgene (Inst); Fujifilm (Inst); G1 Therapeutics; Halozyme (Inst); Inspyr Therapeutics; Insys Therapeutics (Inst); Novartis (Inst); Pieris Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); TD2
Research Funding - Agios (Inst); ARIAD (Inst); BiolineRx (Inst); Boston Biomedical (Inst); Celgene (Inst); Dicerna (Inst); Eisai (Inst); EMD Serono (Inst); Halozyme (Inst); ImClone Systems (Inst); Incyte (Inst); Incyte (Inst); Isis Pharmaceuticals (Inst); MedImmune (Inst); miRNA Therapeutics (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Senhwa Biosciences (Inst); Sillajen (Inst); Sun Biopharma (Inst); Sun Biopharma (Inst); Taiho Pharmaceutical (Inst); Threshold Pharmaceuticals (Inst); Toray Industries (Inst)
Travel, Accommodations, Expenses - ArQule; AstraZeneca; Celgene
 
Amit Mahipal
Research Funding - Astellas Scientific and Medical Affairs Inc (Inst); Karyopharm Therapeutics (Inst); Novartis (Inst)